NOTES TO THE CONSOLIDATED FINANCIAL STATEMENT AS AT DECEMBER 31, 2004
For information regarding the nature of the Group’s business, significant events in early 2005, refer to the contents of the Report on Operations above. It should be noted that the data of the previous year have been suitably reclassified to take into account changes to the schedules of the accounts introduced by Legislative Decree No. 6/2003 and therefore to permit like-for-like comparison with the current year. STRUCTURE AND CONTENTS OF THE CONSOLIDATED FINANCIAL STATEMENTS
The consolidated financial statements have been prepared according to the provisions of Legislative Decree No. 127/1991 and comprise the Balance sheet, Income statement and these Explanatory notes. The Notes to the financial statements are intended to illustrate, analyze and in some cases complete the data of the accounts and comprise the information required by Art. 38 of Legislative Decree No. 127/1991 and other laws in force. Furthermore, all the additional information deemed necessary for true and correct representation of the financial performance and financial position and of the operating performance of the Group is provided, even where not specifically required by law. The consolidated financial statements comprise the financial statements of Diasorin S.p.A. and of the Italian and foreign subsidiaries in which it holds more than 50% of the capital at December 31, 2004. These financial statements have been included in the consolidated accounts according to the line-by-line method as envisaged by Art. 26 of the aforementioned Legislative Decree No. 127/91. Non-operational subsidiaries and those of limited significant within the Group have been valued at cost.
The list of companies consolidated line by line is provided below: Company
HQ
DiaSorin S.p.A.
Italy
DiaSorin Inc.
USA
DiaSorin S.A./N.V. DiaSorin S.A. DiaSorin L.t.d.
% intere Capogruppo 100.00%
Belgium
99.99%
Spain
99.99%
Great Britain
100.00%
DiaSorin L.t.d.a.
Brazil
99.99%
DiaSorin S.A.
France
99.99%
DiaSorin Deutschland GmbH DiaSorin AB
The entire interest in Diasorin Mexico S.A. has been valued at cost.
70
Germany
100.00%
Sweden
100.00%